Clinical Trial Detail

NCT ID NCT02207062
Title Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Washington
Indications

B-cell lymphoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.